Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer

Ching Yao Yang; Ming Huei Fan; Carol H. Miao; Yi Jen Liao; Ray Hwang Yuan; Chao Lien Liu

doi:10.1016/j.omto.2020.05.009

Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer

Ching Yao Yang
, Ming Huei Fan
, Carol H. Miao
, Yi Jen Liao
, Ray Hwang Yuan
, Chao Lien Liu

Research output: Contribution to journal › Article › peer-review

56 Citations (Scopus)

Abstract

Yang et al. developed armed third-generation PD-L1-targeted ACR/CAR T cells utilizing a PD-1/PD-L1 immune checkpoint axis. Both engineered CAR T cells significantly improved tumor control and survival in models of PD-L1-expressed pancreatic cancers.

Original language	English
Pages (from-to)	571-585
Number of pages	15
Journal	Molecular Therapy - Oncolytics
Volume	17
DOIs	https://doi.org/10.1016/j.omto.2020.05.009
Publication status	Published - Jun 26 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

ACR
CAR
PD-1
PD-L1
PDAC

ASJC Scopus subject areas

Molecular Medicine
Oncology
Cancer Research
Pharmacology (medical)

Access to Document

10.1016/j.omto.2020.05.009

Cite this

@article{732dc1c881c84b9e9bca3cf2bfb9985e,

title = "Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer",

abstract = "Yang et al. developed armed third-generation PD-L1-targeted ACR/CAR T cells utilizing a PD-1/PD-L1 immune checkpoint axis. Both engineered CAR T cells significantly improved tumor control and survival in models of PD-L1-expressed pancreatic cancers.",

keywords = "ACR, CAR, PD-1, PD-L1, PDAC",

author = "Yang, \{Ching Yao\} and Fan, \{Ming Huei\} and Miao, \{Carol H.\} and Liao, \{Yi Jen\} and Yuan, \{Ray Hwang\} and Liu, \{Chao Lien\}",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s)",

year = "2020",

month = jun,

day = "26",

doi = "10.1016/j.omto.2020.05.009",

language = "English",

volume = "17",

pages = "571--585",

journal = "Molecular Therapy - Oncolytics",

issn = "2372-7705",

publisher = "Cell Press",

}

TY - JOUR

T1 - Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer

AU - Yang, Ching Yao

AU - Fan, Ming Huei

AU - Miao, Carol H.

AU - Liao, Yi Jen

AU - Yuan, Ray Hwang

AU - Liu, Chao Lien

PY - 2020/6/26

Y1 - 2020/6/26

N2 - Yang et al. developed armed third-generation PD-L1-targeted ACR/CAR T cells utilizing a PD-1/PD-L1 immune checkpoint axis. Both engineered CAR T cells significantly improved tumor control and survival in models of PD-L1-expressed pancreatic cancers.

AB - Yang et al. developed armed third-generation PD-L1-targeted ACR/CAR T cells utilizing a PD-1/PD-L1 immune checkpoint axis. Both engineered CAR T cells significantly improved tumor control and survival in models of PD-L1-expressed pancreatic cancers.

KW - ACR

KW - CAR

KW - PD-1

KW - PD-L1

KW - PDAC

UR - https://www.scopus.com/pages/publications/85087048001

UR - https://www.scopus.com/pages/publications/85087048001#tab=citedBy

U2 - 10.1016/j.omto.2020.05.009

DO - 10.1016/j.omto.2020.05.009

M3 - Article

AN - SCOPUS:85087048001

SN - 2372-7705

VL - 17

SP - 571

EP - 585

JO - Molecular Therapy - Oncolytics

JF - Molecular Therapy - Oncolytics

ER -

Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this